RAP 0.00% 20.5¢ resapp health limited

ResApp Licenses Additional Pneumonia Diagnostic Tool from...

  1. 5,288 Posts.
    lightbulb Created with Sketch. 1126
    ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest
    Brisbane, Australia, 28 April 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has signed an exclusive worldwide license agreement with UniQuest, the main commercialisation company of The University of Queensland, for an additional diagnostic tool that complements ResApp’s existing cough-based diagnostic technology. The tool is a set of machinelearning algorithms that use a combination of clinical features to screen for childhood pneumonia. Unlike ResAppDx, it does not use cough sound analysis, but relies on commonly-taken measurements such as heart rate, temperature, presence of chest in-drawing or oxygen saturation. The technology was developed at The University of Queensland by the team led by Dr Udantha Abeyratne with funding from the Bill and Melinda Gates Foundation and is the subject of a recently filed provisional patent application.
    Pneumonia is the leading cause of mortality for children below 5 years of age. The majority of incidents occur in poor countries where doctors and healthcare workers rely on the WHO/IMCI criteria, which has been shown to yield very low specificity. In a recently published peer-reviewed study (World J Pediatr. 2017 Mar 22. doi: 10.1007/s12519-017-0019-4) the new algorithms achieved a sensitivity of 90% and specificity of 70-72% for diagnosis of childhood pneumonia on a 134-subject dataset, versus 10-38% achieved by the WHO/IMCI criteria. The new algorithms thus deliver an 84% to 655% improvement in specificity.
    “We are pleased to continue to work with Dr Abeyratne’s team at The University of Queensland and license another unique technology which strengthens our product portfolio, in particular for the developing world,” said Tony Keating, CEO and Managing Director of ResApp Health. “These new algorithms represent a significant improvement over the current standard of practice in the developing world and a unique opportunity to deploy an effective pneumonia screening tool in situations where a smartphone is not available or a cough recording is not possible.”
    As part of the license agreement, ResApp will pay UniQuest a royalty on products that use the new algorithms. ResApp also agreed to abide by the Gates Foundation Global Access Objectives and make the technology accessible (with respect to cost, quantity and applicability) to the people most in need within the developing countries of the world.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.